查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864800

內分泌藥物市場按治療領域、藥物類別、給藥途徑、患者年齡層和通路－2025-2032年全球預測

Endocrinology Drugs Market by Therapy Area, Drug Class, Mode of Administration, Patient Age Group, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，內分泌藥物市場規模將達到 1,097.8 億美元，年複合成長率為 7.60%。

關鍵市場統計數據
基準年 2024 610.6億美元
預計年份：2025年 654.3億美元
預測年份 2032 1097.8億美元
複合年成長率 (%) 7.60%

權威概述了治療創新、監管變革和患者​​期望如何重塑內分泌學領域的藥物策略和治療路徑。

由於許多疾病的慢性特徵、生物製藥和小分子藥物的持續創新，以及患者對治療便利性和療效的期望不斷變化，內分泌治療在現代醫療保健中發揮核心作用。在臨床和商業領域，相關人員越來越重視那些能夠改善代謝控制、降低併發症發生率並透過改進製劑和給藥系統來提高患者長期用藥依從性的干涉措施。因此，對於必須在臨床療效和實際應用挑戰之間取得平衡的臨床醫生、商業領袖和政策顧問而言，整合治療創新、監管發展和患者用藥趨勢的研究至關重要。

本執行摘要概述了當前形勢，重點介紹了影響產品策略和患者照護路徑的技術、監管和供應鏈發展。它闡述了糖尿病、甲狀腺疾病、腦下垂體疾病和其他內分泌疾病的治療進展，並強調了將藥理學與數位健康、患者援助計劃和新型分銷模式相結合的重要性。讀者將了解創新、支付方優先事項和全球貿易趨勢如何相互交織，從而影響整個價值鏈的策略規劃和營運執行。

生物製藥、給藥系統、數位療法和法規結構的創新如何共同重塑內分泌治療領域的競爭策略

內分泌學領域正經歷變革性的轉變，這主要得益於生物製藥、胜肽工程和遞送技術的進步，這些進步顯著提高了療效和患者用藥的便利性。新型GLP-1受體促效劑和長效胰島素類似物已確立了新的治療標準，而製劑科學的進步則實現了減少給藥頻率和拓展給藥途徑。同時，數位健康平台和遠端監測工具正與治療方案相結合，以支持患者依從性、劑量調整和個人化治療方案，這些也正在影響臨床試驗設計和上市後證據的產生。

在各個治療領域，商業和法律規範也在不斷發展，以適應加速核准、基於價值的合約和基於績效的報銷模式。這些趨勢正在推動強力的真實世界證據項目，並促進製造商、醫療服務提供者和支付者之間更緊密的合作。供應鏈韌性和生產靈活性也已成為戰略重點，推動對區域生產能力和夥伴關係關係的投資，從而縮短前置作業時間並提高對需求波動的應對力。這些變化正在創造一個環境，​​在這個環境中，卓越的商業化和患者支持對於治療方法的差異化至關重要。

2025年關稅對醫藥生態系統內的供應鏈、籌資策略、生產決策和合約保護的實際影響

2025年推出的關稅和貿易措施為整個醫藥價值鏈的定價、供應鏈設計和籌資策略帶來了新的考量。關稅相關成本的增加使原料藥和成品藥的進口變得更加複雜，促使製造商重新評估其成本結構，並制定應對關稅、物流附加費和合規文件的方案。因此，採購和供應鏈負責人正優先考慮供應商多元化、盡可能選擇近岸外包以及嚴格的庫存管理，以降低邊境相關成本波動帶來的風險。

同時，監管機構和商業夥伴正積極應對不斷變化的貿易環境，強調成本透明轉嫁和合約保障，以抵禦關稅波動的影響。研發計畫也反映了這些趨勢，企業考慮在本地生產關鍵零件，優先採用模組化製造技術以實現高效規模化生產，並與供應商協商長期合約以穩定投入成本。這些務實的因應措施旨在確保患者獲得醫療服務並維持治療的連續性，同時發展能夠適應高成本貿易環境的商業模式。

全面的細分觀點可以清楚地展現跨治療領域、藥物類別、給藥途徑、患者人口統計特徵和通路動態的臨床重點、製劑形式和分銷策略。

細分市場為理解治療價值和商業性機會如何因臨床適應症、分子類別、給藥途徑、患者群體和通路而異提供了一個切實可行的觀點。對比腎上腺疾病、糖尿病、生長遲緩、骨質疏鬆症、腦下垂體疾病和甲狀腺疾病等治療領域與抑鈣素肽、生長激素、胰島素、口服降血糖藥、口服降血糖藥以及副甲狀腺素及其類似物等藥物類別，可以揭示研發複雜性、監管要求和患者依從性挑戰方面的重要模式。不同的給藥途徑（吸入、注射、口服）進一步影響產品定位，而給藥途徑的便利性和穩定性等因素則影響臨床應用和支付方的評估。

患者人口統計細分——成人、老年人和兒童——也影響臨床試驗設計、安全性監測和製劑最佳化的差異，因為不同族群的藥物動力學和依從性行為存在差異。通路，包括醫院、線上和零售藥局，決定產品上市和長期可近性的商業性路徑，影響從低溫運輸物流到病患諮詢機會等方方面面。整合這些細分維度，可以揭示治療創新可能快速擴散的領域、需要更多證據和遞送創新的領域，以及患者支持在維持臨床和商業性成功方面至關重要的領域。

區域法規結構、支付方趨勢和基礎設施因素如何推動美洲、歐洲、中東和非洲以及亞太地區的個人化醫療服務取得策略

區域特徵對產品開發、監管規劃和商業化的策略決策有顯著影響。在美洲，成熟的支付方體系和完善的專科診療路徑有利於差異化治療方法的快速推廣，但報銷壓力和價格敏感性要求提供強力的衛生經濟學證據和結構化的患者支持項目。這種環境有利於那些能展現明確臨床效益、改善病患預後，同時又能為醫療保健系統帶來顯著成本節約的產品。

在歐洲、中東和非洲地區，複雜的監管環境和多樣化的報銷機制要求企業制定個人化的打入市場策略和彈性價格設定方式。由於各地區基礎設施和准入管道存在差異，製造商需要設計差異化的分銷和准入方案，以同時滿足公共醫療採購和私人專科管道的需求。在亞太地區，新技術快速普及和對本土製造的日益重視是顯著的趨勢。不同的監管路徑和市場成熟度為當地企業、共同開發契約以及結合全球專業知識和本地執行能力的混合商業化模式創造了機會。

領先製藥公司採取的策略行動和業務投資優先考慮產品線差異化、生產靈活性和一體化的患者准入解決方案。

產業相關人員正在製定策略應對措施，以應對治療和商業方面的壓力，這些措施強調專業化、營運韌性和夥伴關係。主要企業正優先考慮透過內部創新和外部聯盟來實現產品線差異化，這些聯盟能夠提供互補能力，例如先進的製劑科學、生物製劑工程和數位化依從性平台。策略授權和共同開發契約可以加快產品上市速度，同時分散開發風險，並有助於獲得當地監管的專業知識。

在營運方面，各公司正投資於靈活的生產平台、先進的低溫運輸和品質保證流程，以減少供應中斷並支援國際分銷。商業策略正在加速採用按績效付費合約和整合式患者服務，以確保處方箋被納入處方集並促進長期用藥依從性。同時，中型市場和專科公司正透過提供高度個人化的患者支援和臨床醫生教育計畫來開拓市場，這些計畫與其治療方案相輔相成，並強化了品牌差異化。總而言之，這些舉措反映了整個產業向整合式解決方案的轉變，這種解決方案將臨床價值與實際可及性相結合。

產業領導者應重點關注以下切實可行的策略事項：加強供應鏈韌性、強化與支付方的夥伴關係以及將數位化能力融入醫療服務。

產業領導者應採取多管齊下的策略，在科學創新、實際應用和業務永續營運之間取得平衡。首先，應優先考慮供應鏈多元化和短期緊急時應對計畫，以降低貿易相關成本衝擊的影響。應就關鍵原料藥(API) 建立多源採購協議，並考慮建立區域生產夥伴關係，以減少對單一地區的依賴。同時，應加快對製劑和給藥方式創新的投資，以提高患者依從性、減輕給藥負擔，並擴大成人、老年人和兒童患者的覆蓋範圍。

第二，透過早期衛生經濟學建模和結果資料收集，加強與支付方的合作，以支持基於價值的合約。制定真實世界證據項目和患者報告結果 (PRO)舉措，以證明長期療效並為定價討論提供基礎。第三，建立夥伴關係，將數位健康能力融入醫療服務，實現遠端監測、依從性支援和個人化給藥方案。最後，將監管前瞻性納入研發計劃，在適當情況下利用加速核准途徑，並設計符合上市後證據要求的核准方案。透過共同實施這些舉措，各機構將能夠更好地提供差異化的臨床價值，同時有效管理商業性和營運風險。

嚴謹的多方面研究途徑，結合專家訪談、監管審查、臨床證據綜合和分段分析，驗證了檢驗並指出了其局限性。

本研究整合了透過與臨床醫生、支付方、供應鏈經理和行業高管的專家訪談收集的關鍵發現，並結合對監管指導文件、臨床文獻和公共公告的全面審查。調查方法方法強調三角驗證，將從相關人員對話中獲得的見解與監管記錄、已發表的臨床試驗結果和商業資訊披露進行交叉比對，以檢驗結論反映出趨同的證據基礎。研究採用細分映射法，將治療適應症、藥物類別、給藥途徑、年齡層和分銷管道與臨床和商業性屬性相匹配。

品管包括與領域專家進行交叉檢驗、反覆進行主題提煉，以及針對供應鏈和政策相關解讀的敏感度檢查。局限性包括貿易措施的動態性以及政策實施與可觀察到的商業性影響之間的滯後性。該分析恰當地區分了已記錄的變化和可能出現的近期應對措施。資訊來源選擇和調查方法的透明度使讀者能夠評估研究結果對其特定組織環境的適用性，並可要求針對特定領域或地區進行客製化的深度分析。

綜合分析研究結果，強調整合證據產生、加強供應鏈韌性以及相關人員合作對於實現治療進展的重要性。

治療方法、支付方期望的轉變以及貿易相關的成本壓力交織在一起，需要研發、生產和商業部門協同應對。胜肽工程、生物製藥和遞送系統的治療進展為改善患者療效創造了新的機遇，但要充分發揮這些潛力，需要製定切實可行的策略，以確保治療的可負擔性、可及性和依從性。那些將實證醫學研究與以病人為中心的服務模式和穩健的供應鏈結合的機構，將更有能力把臨床創新轉化為持久的健康效益。

展望未來，製造商、醫療服務提供者、支付方和監管機構之間的持續合作對於應對不斷變化的報銷模式和地緣政治對貿易的影響至關重要。對區域製造、數位健康整合和真實世界證據能力的策略性投資將帶來永續的競爭優勢。最終，成功取決於將卓越的科學技術與營運適應能力以及各相關人員之間的合作相結合，以確保治療方面的進步能夠轉化為患者照護方面可衡量的改善。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • GLP-1受體促效劑的應用範圍已從糖尿病管理擴展到肥胖症治療；口服甲狀腺刺激素受體調變器獲得監管部門核准，為甲狀腺機能低下症患者提供了一種非侵入性治療選擇；數位健康平台與智慧胰島素筆的整合
  • 口服甲狀腺刺激素受體調變器的核准為甲狀腺機能低下症患者提供了一種非侵入性治療選擇。
  • 數位健康平台與智慧胰島素筆的整合可提高糖尿病患者的治療順從性和血糖控制效果。
  • 針對罕見內分泌疾病的個人化胜肽療法正透過精準醫療舉措廣受關注。
  • 針對腎上腺功能不全的新興聯合治療既滿足了皮質醇替代的需求，也滿足了免疫調節的需求。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 內分泌藥物市場（依治療領域分類）

  • 腎上腺疾病
  • 糖尿病
  • 生長遲緩
  • 骨質疏鬆症
  • 腦下垂體疾病
  • 甲狀腺疾病

第9章 內分泌藥物市場（依藥物類別分類）

  • 抑鈣素肽
  • 生長激素
  • 胰島素
  • 口服降血糖藥
  • 口服降血糖藥物
  • 副甲狀腺素及其類似物

第10章 內分泌藥物市場依給藥途徑分類

  • 吸入劑
  • 注射
  • 口服

第11章 依患者年齡層分類的內分泌藥物市場

  • 成人版
  • 老年人
  • 孩子們

第12章 內分泌藥物市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 內分泌藥物市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 內分泌藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國內分泌藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • AbbVie Inc.
    • Ascendis Pharma A/S
    • AstraZeneca PLC
    • Bayer AG
    • Biocon Limited
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • CHIESI Farmaceutici SpA
    • Eli Lilly and Company
    • Endo, Inc.
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline PLC
    • Hanmi Pharm Co., Ltd.
    • Ipsen Pharma
    • Johnson & Johnson Services, Inc.
    • MacroGenics, Inc.
    • MannKind Corporation
    • Merck & Co., Inc.
    • Novartis AG
    • Novo Nordisk A/S
    • Oramed Pharmaceuticals Inc.
    • Pfizer Inc.
    • Precigen, Inc.
    • Sanofi SA
    • Shenzhen Microchip Biotechnology Co., Ltd.
    • Sun Pharmaceutical Industries Limited
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-D1342F184FD3

The Endocrinology Drugs Market is projected to grow by USD 109.78 billion at a CAGR of 7.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 61.06 billion
Estimated Year [2025] USD 65.43 billion
Forecast Year [2032] USD 109.78 billion
CAGR (%) 7.60%

An authoritative overview of how therapeutic innovation, regulatory shifts, and patient expectations are reshaping endocrinology drug strategies and care pathways

Endocrinology therapeutics occupy a central role in modern healthcare due to the chronic nature of many conditions, the ongoing innovation in biologics and small molecules, and evolving patient expectations for convenience and outcomes. Across clinical and commercial settings, stakeholders increasingly prioritize interventions that improve metabolic control, reduce complication rates, and support long-term adherence through improved formulations and delivery systems. Consequently, research that synthesizes therapeutic innovation, regulatory dynamics, and patient access trends is essential for clinicians, commercial leaders, and policy advisors who must balance clinical efficacy with real-world implementation challenges.

This executive summary frames the contemporary landscape by highlighting technological, regulatory, and supply chain developments that shape product strategy and patient care pathways. It contextualizes therapeutic progress in diabetes, thyroid, pituitary, and other endocrine conditions while emphasizing the importance of integrated approaches that combine pharmacology with digital health, patient support programs, and novel distribution models. Readers are guided to consider how innovation, payer priorities, and global trade dynamics converge to influence strategic planning and operational execution across the value chain.

How innovations in biologics, delivery systems, digital therapeutics, and regulatory frameworks are jointly redefining competitive strategies across endocrinology treatments

The endocrinology landscape is undergoing transformative shifts driven by advances in biologics, peptide engineering, and delivery technologies that enhance both efficacy and patient convenience. Novel GLP-1 receptor agonists and long-acting insulin analogs have catalyzed new standards of care, while improvements in formulation science enable less frequent dosing and alternative administration routes. Concurrently, digital health platforms and remote monitoring tools are integrating with therapeutic regimens to support adherence, titration, and personalized care plans, which in turn influence clinical trial design and post-market evidence generation.

Beyond therapeutics, commercial and regulatory frameworks are evolving to accommodate accelerated approvals, value-based contracting, and outcomes-based reimbursement. These trends incentivize robust real-world evidence programs and closer alignment between manufacturers, providers, and payers. Supply chain resilience and manufacturing flexibility have also become strategic priorities, prompting investments in regional production capabilities and partnerships that reduce lead times and improve responsiveness to demand fluctuations. Taken together, these shifts are creating an environment where therapeutic differentiation must be matched by excellence in commercialization and patient support.

Realistic implications of 2025 tariff measures on supply chains, sourcing strategies, manufacturing decisions, and contractual protections within the pharmaceutical ecosystem

The introduction of tariffs and trade measures in 2025 has introduced new considerations for pricing, supply chain design, and sourcing strategies across the pharmaceutical value chain. Tariff-related costs increase the complexity of importing active pharmaceutical ingredients and finished products, thereby prompting manufacturers to revisit cost structures and engage in scenario planning for customs duties, logistics surcharges, and compliance-related documentation. Consequently, procurement teams and supply chain executives have prioritized supplier diversification, nearshoring where feasible, and tighter inventory management to mitigate exposure to border-related cost volatility.

In parallel, regulatory authorities and commercial partners are responding to the changed trade environment by emphasizing transparency in cost pass-through and contractual protections that address tariff fluctuations. Research and development planning also reflects these dynamics; companies are exploring localized manufacturing for critical components, prioritizing modular production technologies that scale efficiently, and negotiating long-term agreements with suppliers to stabilize input costs. These pragmatic responses seek to preserve patient access and maintain continuity of care while adapting commercial models to a higher-cost trading environment.

Integrated segmentation perspectives that reveal clinical, formulation, and distribution priorities across therapy areas, drug classes, administration modes, demographics, and channel dynamics

Segmentation provides a practical lens for understanding how therapeutic value and commercial opportunity vary across clinical indications, molecule classes, modes of delivery, patient demographics, and distribution pathways. When therapy areas such as Adrenal Disorders, Diabetes, Growth Disorders, Osteoporosis, Pituitary Disorders, and Thyroid Disorders are juxtaposed with drug classes that include Calcitonin Peptides, Growth Hormone, Insulin, Oral Antidiabetics, Oral Hypoglycemics, and Parathyroid Hormones & Analogs, important patterns emerge in terms of development complexity, regulatory requirements, and patient adherence challenges. Mode of administration distinctions-Inhalable, Injectable, and Oral-further shape product positioning, with route-specific convenience and stability considerations influencing clinical adoption and payer evaluations.

Patient age group segmentation between Adult, Geriatric, and Pediatric populations also drives differentiated clinical trial design, safety monitoring, and formulation optimization, given varied pharmacokinetics and adherence behaviors across cohorts. Distribution channels that encompass Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies determine the commercial pathway for product launch and long-term access, affecting everything from cold chain logistics to patient counseling opportunities. Integrating these segmentation dimensions illuminates where therapeutic innovations are likely to achieve rapid uptake, where additional evidence or delivery innovation is necessary, and where patient support will be a decisive factor in sustained clinical and commercial success.

How regional regulatory frameworks, payer dynamics, and infrastructure considerations drive tailored access strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics materially influence the strategic calculus for product development, regulatory planning, and commercialization. In the Americas, a mature payer ecosystem and established specialty care pathways support rapid adoption of differentiated therapies, although reimbursement pressure and price sensitivity require robust health economic evidence and well-structured patient support programs. This environment favors products that demonstrate clear clinical benefit and improved patient outcomes while delivering demonstrable cost offsets for healthcare systems.

In Europe, Middle East & Africa, regulatory complexity and heterogeneous reimbursement mechanisms necessitate tailored market entry strategies and flexible pricing approaches. Regional variation in infrastructure and access pathways means that manufacturers must design differentiated distribution and access programs that accommodate public healthcare procurement as well as private specialty channels. In the Asia-Pacific region, rapid adoption of new technologies and a growing emphasis on domestic manufacturing are notable trends. Diverse regulatory pathways and varying degrees of market maturity create opportunities for partnerships with local firms, co-development arrangements, and hybrid commercialization models that balance global expertise with local execution capabilities.

Strategic behaviors and operational investments by leading pharmaceutical companies that prioritize pipeline differentiation, manufacturing flexibility, and integrated patient access solutions

Industry actors are responding to therapeutic and commercial pressures with strategic moves that emphasize specialization, operational resilience, and partnership. Leading companies are prioritizing pipeline differentiation through both internal innovation and external alliances that deliver complementary capabilities, such as advanced formulation science, biologics engineering, or digital adherence platforms. Strategic licensing and co-development arrangements help accelerate time-to-market while distributing development risk and enabling access to local regulatory expertise.

Operationally, firms are investing in flexible manufacturing platforms, cold chain sophistication, and quality assurance processes that reduce supply disruptions and support international distribution. Commercial strategies increasingly incorporate outcomes-oriented contracting and integrated patient services to secure formulary positions and nurture long-term adherence. In parallel, mid-sized and specialty companies are carving out niches by delivering high-touch patient support and clinician education programs that complement therapeutic profiles and strengthen brand differentiation. Collectively, these behaviors reflect a sector-wide pivot toward integrated solutions that pair clinical value with pragmatic access mechanisms.

Practical strategic priorities for industry leaders to enhance supply chain resilience, strengthen payer partnerships, and integrate digital capabilities into therapeutic offerings

Industry leaders should adopt a multifaceted strategy that aligns scientific innovation with pragmatic access and operational resilience. First, prioritize supply chain diversification and near-term contingency planning to reduce exposure to trade-related cost shocks. Establish multi-sourcing agreements for critical APIs and consider regional production partnerships that lower dependency on single geographies. Simultaneously, accelerate investments in formulation and delivery innovations that improve adherence, reduce administration burden, and expand the addressable patient population across adult, geriatric, and pediatric cohorts.

Second, strengthen payer engagement through early health economic modelling and outcomes data collection to support value-based contracting. Develop real-world evidence programs and patient-reported outcomes initiatives that substantiate long-term benefits and inform pricing discussions. Third, cultivate partnerships that bring digital health capabilities into therapeutic offerings, enabling remote monitoring, adherence support, and personalized dosing regimens. Finally, embed regulatory foresight into R&D planning to leverage expedited pathways where appropriate and to design registrational programs that reflect post-market evidence requirements. Collectively, these actions will position organizations to deliver differentiated clinical value while managing commercial and operational risk.

A rigorous, multi-method research approach combining expert interviews, regulatory review, clinical evidence synthesis, and segmented analysis to validate insights and identify limitations

This research synthesizes primary insights gathered through expert interviews with clinicians, payers, supply chain managers, and industry executives alongside a thorough review of regulatory guidance documents, clinical literature, and public policy announcements. The methodological approach emphasizes triangulation: findings from stakeholder conversations were validated against regulatory records, published clinical trial results, and operational disclosures to ensure that conclusions reflect a convergent evidence base. Segmentation mapping was applied to align therapeutic indications, drug classes, modes of administration, age groups, and distribution channels with clinical and commercial attributes.

Quality control included cross-validation by domain experts, iterative refinement of themes, and sensitivity checks on supply chain and policy-related interpretations. Limitations stem from the evolving nature of trade measures and the lag between policy implementation and observable commercial impacts; where appropriate, the analysis distinguishes between documented changes and plausible near-term responses. Transparency about sources and methodological choices enables readers to assess the applicability of insights to their specific organizational contexts and to request bespoke deep dives focused on particular segments or geographies.

Consolidating insights to emphasize the imperative for integrated evidence generation, supply chain resilience, and stakeholder collaboration to realize therapeutic advances

The confluence of therapeutic innovation, changing payer expectations, and trade-related cost pressures requires a coordinated response across R&D, manufacturing, and commercial functions. Therapeutic advances in peptide engineering, biologics, and delivery systems are creating new opportunities for improved patient outcomes, yet realizing that potential depends on pragmatic strategies that ensure affordability, access, and adherence. Organizations that integrate evidence generation with patient-centric service models and resilient supply chains will be best positioned to convert clinical innovation into sustained health impact.

Looking ahead, continued collaboration among manufacturers, providers, payers, and regulators will be essential to navigate evolving reimbursement paradigms and to respond to geopolitical influences on trade. Strategic investments in regional manufacturing, digital health integration, and real-world evidence capabilities will provide durable advantages. Ultimately, success will hinge on the ability to combine scientific excellence with operational adaptability and stakeholder alignment so that therapeutic advances translate into measurable improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growth of GLP-1 receptor agonists for obesity management beyond diabetes management
  • 5.2. Introduction of insulin biosimilars fueling price competition and market access challenges in emerging economies
  • 5.3. Regulatory approval of oral thyrotropin receptor modulators offering noninvasive treatment options for hypothyroidism patients
  • 5.4. Integration of digital health platforms with smart insulin pens improving adherence and glycemic control outcomes in diabetics
  • 5.5. Personalized peptide therapies targeting rare endocrine disorders gaining traction through precision medicine initiatives
  • 5.6. Emerging combination therapies for adrenal insufficiency addressing both cortisol replacement and immune modulation requirements

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endocrinology Drugs Market, by Therapy Area

  • 8.1. Adrenal Disorders
  • 8.2. Diabetes
  • 8.3. Growth Disorders
  • 8.4. Osteoporosis
  • 8.5. Pituitary Disorders
  • 8.6. Thyroid Disorders

9. Endocrinology Drugs Market, by Drug Class

  • 9.1. Calcitonin Peptides
  • 9.2. Growth Hormone
  • 9.3. Insulin
  • 9.4. Oral Antidiabetics
  • 9.5. Oral Hypoglycemics
  • 9.6. Parathyroid Hormones & Analogs

10. Endocrinology Drugs Market, by Mode of Administration

  • 10.1. Inhalable
  • 10.2. Injectable
  • 10.3. Oral

11. Endocrinology Drugs Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Endocrinology Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Endocrinology Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Endocrinology Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Endocrinology Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. AbbVie Inc.
    • 16.3.3. Ascendis Pharma A/S
    • 16.3.4. AstraZeneca PLC
    • 16.3.5. Bayer AG
    • 16.3.6. Biocon Limited
    • 16.3.7. Boehringer Ingelheim International GmbH
    • 16.3.8. Bristol-Myers Squibb Company
    • 16.3.9. CHIESI Farmaceutici S.p.A.
    • 16.3.10. Eli Lilly and Company
    • 16.3.11. Endo, Inc.
    • 16.3.12. F. Hoffmann-La Roche Ltd.
    • 16.3.13. GlaxoSmithKline PLC
    • 16.3.14. Hanmi Pharm Co., Ltd.
    • 16.3.15. Ipsen Pharma
    • 16.3.16. Johnson & Johnson Services, Inc.
    • 16.3.17. MacroGenics, Inc.
    • 16.3.18. MannKind Corporation
    • 16.3.19. Merck & Co., Inc.
    • 16.3.20. Novartis AG
    • 16.3.21. Novo Nordisk A/S
    • 16.3.22. Oramed Pharmaceuticals Inc.
    • 16.3.23. Pfizer Inc.
    • 16.3.24. Precigen, Inc.
    • 16.3.25. Sanofi S.A
    • 16.3.26. Shenzhen Microchip Biotechnology Co., Ltd.
    • 16.3.27. Sun Pharmaceutical Industries Limited
    • 16.3.28. Takeda Pharmaceutical Company Limited
    • 16.3.29. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ENDOCRINOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ENDOCRINOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ENDOCRINOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADRENAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PITUITARY DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY CALCITONIN PEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROWTH HORMONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL ANTIDIABETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL HYPOGLYCEMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PARATHYROID HORMONES & ANALOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INHALABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 256. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 257. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. GCC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 280. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 281. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 282. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 292. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 293. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 294. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 295. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 296. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 297. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. G7 ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 304. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 305. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 306. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 307. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. NATO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 316. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 317. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 320. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 321. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 322. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 323. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 324. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 325. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
  • TABLE 326. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2025-2032 (USD MILLION)
  • TABLE 327. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 328. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 329. CANADA ENDOCRINOLOGY DRUG